Boston Scientific Corp. (NYSE: BSX) reported Q1 adjusted-EPS of $0.15, $0.07 better than the analyst estimate of $0.08. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.86 billion.

Boston Scientific Corp. sees Q2 2012 adjusted EPS of $0.14-$0.17, versus the consensus of $0.10. Boston Scientific Corp. sees Q2 2012 revenue of $1.85-$1.95 billion, versus the consensus of $1.9 billion.

Boston Scientific Corp. sees adjusted FY2012 EPS of $0.60-$0.70, versus the consensus of $0.42. Boston Scientific Corp. sees FY2012 revenue of $7.35-$7.65 billion, versus the consensus of $7.48 billion.

For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.

Earnings Guidance